Compare · DXCM vs NSPR
DXCM vs NSPR
Side-by-side comparison of DexCom Inc. (DXCM) and InspireMD Inc. (NSPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NSPR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.11B, about 1634.7x NSPR ($20.3M).
- Over the past year, DXCM is up 28.6% and NSPR is down 68.5% - DXCM leads by 97.1 points.
- DXCM has been more active in the news (10 items in the past 4 weeks vs 5 for NSPR).
- DXCM has more recent analyst coverage (25 ratings vs 1 for NSPR).
- Company
- DexCom Inc.
- InspireMD Inc.
- Price
- $87.72-1.99%
- $0.76+0.75%
- Market cap
- $33.11B
- $20.3M
- 1M return
- -3.66%
- -13.22%
- 1Y return
- +28.61%
- -68.54%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2005
- News (4w)
- 10
- 5
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
InspireMD Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
- EVP, Chief Financal Officer Sylvain Jereme M sold $302,936 worth of shares (3,638 units at $83.27) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 146,828 units (SEC Form 4)
- Director Boehnlein Glenn S was granted 5,841 shares (SEC Form 4)
- New insider Boehnlein Glenn S claimed ownership of 42 shares (SEC Form 3)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Appoints Glenn Boehnlein to Board of Directors
- Dexcom Announces Upcoming Conference Presentation
Latest NSPR
- SEC Form 4 filed by Director Roubin Gary S
- SEC Form 4 filed by Director Berman Michael
- SEC Form 4 filed by Director Stuka Paul
- InspireMD Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
- InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by InspireMD Inc.
- InspireMD to Announce Second Quarter 2026 Financial Results
- InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing
- InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits